Business Information
The group's principal activity is to discover, develop, manufacture and market products for treatment and prevention of infectious diseases, immune system disorders and cancer. The products of the group include synagis, flumist and ethyol. Synagis is a humanized monoclonal antibody for the prevention of respiratory tract disease caused by respiratory syncytial virus in pediatric patients. Ethyol is used to prevent certain unwanted side effects of specific types of chemo and radiotherapies that are used to treat cancer. Flumist is a vaccine for the prevention of disease caused by influenza a and b viruses. The other products of the group are cytogam, neutrexin, and respigam. These products are used for prevention of disease associated with kidney, liver or heart transplantation, for the treatment of aids patients and for the treatment of respiratory virus disease in children. The group operates five facilities in the United States and Europe.
|
|
Name |
Title
|
Email
|
| James Young | Pres. - Research, Development | N/A | | Lota Zoth | Sr. VP, CFO | N/A | | William Bertrand | Sr. VP - Legal Affairs, General Counsel, Corporate Compliance Officer | N/A | | Bernardus MacHielse | Exec. VP - Operations | N/A | | Edward Mathers | Dir., Exec. VP - Corporate Development, Venture | N/A |
|
|
Year |
Sales |
Net Income |
| 2005 | 1,243,900 | (16,600) | | 2004 | 1,141,100 | (3,800) | | 2003 | 1,054,334 | 183,204
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
